Blake A Rowe

US Patent:

59624191, Oct 5, 1999

Filed:

May 17, 1995

Appl. No.:

8/442514

Inventors:

Ian Alexander McDonald - San Diego CA
Elisabeth Albrecht - San Diego CA
Benito Munoz - San Diego CA
Blake Alan Rowe - San Diego CA
Robert Steven Siegel - San Diego CA
Steven Lee Wagner - Del Mar CA

Assignee:

SIBIA Neurosciences, Inc. - La Jolla CA

International Classification:

A61K 3805

US Classification:

514 19

Abstract:

Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R. sub. 1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmethyl; R. sub. 2, R. sub. 4, and R. sub. 8 are each preferably independently methyl or ethyl; R. sub. 3 is preferably iso-butyl or phenyl; Q is preferably --C(O)--; R. sub. B is preferably iso-butyl; R. sub. A is --(T). sub. m --(D). sub. m --R. sub. 1, in which T is preferably oxygen or NH, m is 0 or 1, and D is preferably C. sub. 1-4 alkyl or C. sub. 2-4 alkenyl; and X is preferably an aldehyde,. alpha. -ketoester or. alpha. -ketoamide.

US Patent:

61531715, Nov 28, 2000

Filed:

May 17, 1995

Appl. No.:

8/443048

Inventors:

Blake Alan Rowe - San Diego CA
Robert Steven Siegel - San Diego CA
Steven Lee Wagner - Del Mar CA

Assignee:

SIBIA Neurosciences, Inc. - La Jolla CA

International Classification:

G01N 3353

US Classification:

424 91

Abstract:

Methods for identifying compounds that can be used for treatment of neurodegenerative diseases, for monitoring the progression of these diseases, and for monitoring therapeutic intervention of these diseases are provided. These methods are effected by determining the relative amount of. alpha. -sAPP and the ratio of. alpha. -sAPP to total sAPP in body fluids, tissues or in cell culture.

US Patent:

57144710, Feb 3, 1998

Filed:

May 17, 1995

Appl. No.:

8/443901

Inventors:

Blake Alan Rowe - San Diego CA
Robert Steven Siegel - San Diego CA
Steven Lee Wagner - Del Mar CA

Assignee:

SIBIA Neurosciences, Inc. - La Jolla CA

International Classification:

G01N 3353
G01N 33543
G01N 33561
C07K 1300

US Classification:

514 19

Abstract:

Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R. sub. 1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R. sub. 2, R. sub. 4, and R. sub. 8 are each independently methyl or ethyl; R. sub. 3 is preferably iso-butyl or phenyl; R. sub. 5 is preferably iso-butyl; R. sub. 6 is H or methyl; R. sub. 7 --(Q). sub. n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R. sub. 8 is preferbly iso-butyl; R. sub. A =--(T). sub. m --(D). sub. m --R. sub. 1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C. sub. 3-4 alkenyl being more preferred; and X is preferably an. alpha. -ketoester or. alpha.